Withaferin A activates TRIM16 for its anti-cancer activity in melanoma

Although selective BRAF inhibitors and novel immunotherapies have improved short-term treatment responses in metastatic melanoma patients, acquired resistance to these therapeutics still represent a major challenge in clinical practice. In this study, we evaluated the efficacy of Withaferin A (WFA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, Zsuzsanna, Cheung, Belamy B., Tsang, Wing, Tan, Owen, Herath, Mika, Ciampa, Olivia C., Shadma, Fatima, Carter, Daniel R., Marshall, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665169/
https://www.ncbi.nlm.nih.gov/pubmed/33184347
http://dx.doi.org/10.1038/s41598-020-76722-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665169/
https://www.ncbi.nlm.nih.gov/pubmed/33184347
http://dx.doi.org/10.1038/s41598-020-76722-x

Ejemplares similares